![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 22, 2007 6:34:26 PM
Clinical / Regulatory / Litigation Calendar
[Please keep entries up to date! See updating procedure at the end of this post.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: CVTX
ACHN – See GILD
ADLR – Approvable letter for Entereg issued 11/6/06 requesting safety data due in 2Q07.
AGIX – ARISE data at ACC March 24-27, 2007.
AMGN – Vectibix PACCE trial in 1st-line CRC (Avastin+FOLFOX+/-Vectibix) interim PFS based on 25% of events: 2Q07 (probably ASCO). (PACCE showed no benefit vs control in RR.) Vectibix final OS from ‘408’ study: any day (low chance of hitting endpoint).
AMLN – Phase-3 LAR results: 2H07; Byetta monotherapy results: 2H07.
ANDS – ANA975 for HCV placed on hold 6/26/06 due to preclinical safety issue; human trials expected to resume at end of 2H07 following FDA analysis of animal tox study.
ANDS – ANA380 in HBV: phase-2b to begin “sometime in 2007.”
ANOR / AOM.TO – pivotal AMD3100 results any day.
ASPM – Interim data from BRITE trial in depression: scientific conference in 2Q07.
BMY – Plavix trial begins 1/22/07.
BMY – Erbitux: see IMCL.
BOMSF -reporting pivotal MBP8298 results 2 years roughly
CEPH – Nuvigil for EDS approvable letter received 4/30/06; on 12/7/06, FDA said it was still studying one case of suspected SJS in Sparlon data set.
CLSC - Two phase 3 Trials 1600-2000 patients to complete in calendar Q4 with public " top line data" on results anticipated for calendar Q1 07. This is a 10 week trial.
COLY – Phase-3 PF-3512676 in NSCLC (by PFE): late 2007 or 2008 (2 trials).
COR – Go/no-go decision on CX-717: April/May 2007 following FDA review of the tox report now in preparation by COR’s CRO. (FDA clinical hold was partially lifted 10/9/06.)
CORT – Phase-3 trials of Corlux for psychotic major depression: ‘06’ trial results any day. (The first phase-3 trial called ’07’ reported failed results on 8/25/06; the 2nd phase-3 trial called ‘09’ reported failed results 9/29/06).
CRME - IV RSD1235 NDA refiled, FDA decision likely 4th qtr/07.
CVTX - Ranexa MERLIN data at ACC March 24-27, 2007.
CYT.TO - Initiated pivotal A-fib trial Oct/06. Results timing, will update when company provides timeline.
CYPB – Phase-3 Milnacipran in fibromyalgia, second phase-3 results: mid 2007 (#msg-9132392).
DDSS (formerly LBPFF) – Response to and appeal of Tramadol approvable letter submitted 12/20/06.
DNA – Avastin in breast cancer: FDA requested additional data confirmation on 9/11/06; resubmission by DNA pending.
DNDN – Provenge BLA: advisory panel expected in March 2007; PDUFA date mid-May 2007.
DNDN – 9902b study: enrollment complete in 2007; interim data look 1H08.
FRX - Milnacipran in fibromyalgia: see CYPB.
GILD – Viread for HBV: phase-3 results 4Q07, NDA (if successful) 1H08.
GILD – GS9190 for HCV: start phase-1 any day.
GPCB – Satraplatin SPARC trial: final overall survival: fall 2007. (The trial hit the primary PFS endpoint on 9/24/06; interim OS look announced on 6/8/06 failed to meet threshold for unblinding.)
GTCB – ATryn EU launch for HD: June, 2007.
GTCB – ATryn DIC program in EU: start of ph-2 (by Leo Pharma) any day.
GTCB – ATryn ph-3 for HD in U.S.: complete enrollment 1H07, submit BLA 2H07.
GTCB – Merrimack MM-093 phase-2b in RA, phase-2 in psoriasis to be presented at EULAR in June 2007.
GTOP – Final MyVax results Dec 07.
IDIX – Tyzeka for HBV action date in EU, China: early 2007 (approved by FDA 10/25/06).
IDIX – Tyzeka phase-3 in decompensated liver disease: enrollment complete in 1Q07 (75% complete as of 9/27/06).
IDIX – NM283+ribavirin drug-interaction study: preliminary data at EASL.
IMCL – (See #msg-9218093 for selected Erbitux trials):
1) CRSYTAL trial in first-line CRC hit its PFS endpoint (announced 1/10/07); full data release at ASCO in June, 2007.
2) Erbitux in NSCLC. OS in 1st-line FLEX study: 2H07.
3) Erbitux in pancreatic cancer, SWOG trial: 1Q07.
ISA.TO - Begin European/Cdn pivotal psoriasis trials this qtr, begin U.S. pivotal psoriasis 07, complete enrollment in renal Phase IIb & also interim renal data 1st qtr 07.
ITMN – Phase-1 PK data for ITMN-191: 2H07.
JNJ: CoStar (CONR) data from U.S. pivotal trial: March 2007 at ACC
LBPFF – see DDSS
Merrimack: see GTCB
MS.TO - Complete enrollment in pivotal Secondary Progressive MS trial this year, possible interim results 2007, trial results in 2008.
Novocell – see SRDX
NRMX, NRM.TO – North American Alzhemed trial complete Jan 07, results to follow. European Alzhemed trial complete 1H08 (?). Kiacta (Fibrillex) received an approvable letter on 8/11/06.
NRPH – NRP104 in pediatric ADHD: approvable letter 10/6/06; full approval pending DEA scheduling.
NVS – Galvus PDUFA date late Feb 2007.
NVS – Tekturna PDUFA date mid Mar 2007.
NVS – Tifacogin: enrollment complete 1H07 (#msg-15157973).
PHRM – See GPCB.
PPHM - Bavituximab phase 1B HCV; four doses monotherapy over 14 days, followed for 12 weeks post-therapy, in previous non-responders/relapsers. Patient enrollment completed Oct 24, trial results due 1Q 07.
PPHM - solid tumor 8-week chemo & Bavituximab combination therapy, info due 1Q '07.
RPRX
Proellex
*Uterine Fibroids Phase 2 (U.S.) Full Phase 2 data (mid-2007)
*One year extension data (4Q2007)
*Initiate pivotal trials (YE2007)
*Endometriosis Phase 1/2 (Europe) Full Phase 1/2 data (3Q2007)
*Initiate U.S. Phase 2 (mid-2007)
Androxal
*Male Secondary Hypogonadism Non-pivotal Phase 3 (U.S.) Full non-pivotal Phase 3 data (3Q2007)
*Initiate first pivotal Phase 3 (around YE2007)
SGP – Ph-2 data for SCH 503034 in HCV: 2H07
SNY – Acomplia PDUFA date: 4/26/07.
SNY – Plavix litigation: trial begins 1/22/07.
Speedel – See NVS.
SPPI – See GPCB.
SRDX - Novocell phase-1/2 trial in type-1 diabetes: late summer 2007 (enrollment complete 8/30/06).
TH.TO -Begin confirmatory TH9507 HIV Associated Lipodystropy trial 1st qtr/07
VRTX – PROVE-1/PROVE-2/PROVE-3 timetable: see #msg-12267294
YMI – AeroLEF final results any day (interim results announced on 9/27/06 failed to meet threshold).
--
Procedure For Updating Clinical-Trials List
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old list. You can find a pointer to this list in the iBox at the top of the main message-board screen.
2. Make your additions or modifications, inserting any new items in alphabetical order.
3. Post the updated text in a new message in reply to the message with the old list.
[Please keep entries up to date! See updating procedure at the end of this post.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: CVTX
ACHN – See GILD
ADLR – Approvable letter for Entereg issued 11/6/06 requesting safety data due in 2Q07.
AGIX – ARISE data at ACC March 24-27, 2007.
AMGN – Vectibix PACCE trial in 1st-line CRC (Avastin+FOLFOX+/-Vectibix) interim PFS based on 25% of events: 2Q07 (probably ASCO). (PACCE showed no benefit vs control in RR.) Vectibix final OS from ‘408’ study: any day (low chance of hitting endpoint).
AMLN – Phase-3 LAR results: 2H07; Byetta monotherapy results: 2H07.
ANDS – ANA975 for HCV placed on hold 6/26/06 due to preclinical safety issue; human trials expected to resume at end of 2H07 following FDA analysis of animal tox study.
ANDS – ANA380 in HBV: phase-2b to begin “sometime in 2007.”
ANOR / AOM.TO – pivotal AMD3100 results any day.
ASPM – Interim data from BRITE trial in depression: scientific conference in 2Q07.
BMY – Plavix trial begins 1/22/07.
BMY – Erbitux: see IMCL.
BOMSF -reporting pivotal MBP8298 results 2 years roughly
CEPH – Nuvigil for EDS approvable letter received 4/30/06; on 12/7/06, FDA said it was still studying one case of suspected SJS in Sparlon data set.
CLSC - Two phase 3 Trials 1600-2000 patients to complete in calendar Q4 with public " top line data" on results anticipated for calendar Q1 07. This is a 10 week trial.
COLY – Phase-3 PF-3512676 in NSCLC (by PFE): late 2007 or 2008 (2 trials).
COR – Go/no-go decision on CX-717: April/May 2007 following FDA review of the tox report now in preparation by COR’s CRO. (FDA clinical hold was partially lifted 10/9/06.)
CORT – Phase-3 trials of Corlux for psychotic major depression: ‘06’ trial results any day. (The first phase-3 trial called ’07’ reported failed results on 8/25/06; the 2nd phase-3 trial called ‘09’ reported failed results 9/29/06).
CRME - IV RSD1235 NDA refiled, FDA decision likely 4th qtr/07.
CVTX - Ranexa MERLIN data at ACC March 24-27, 2007.
CYT.TO - Initiated pivotal A-fib trial Oct/06. Results timing, will update when company provides timeline.
CYPB – Phase-3 Milnacipran in fibromyalgia, second phase-3 results: mid 2007 (#msg-9132392).
DDSS (formerly LBPFF) – Response to and appeal of Tramadol approvable letter submitted 12/20/06.
DNA – Avastin in breast cancer: FDA requested additional data confirmation on 9/11/06; resubmission by DNA pending.
DNDN – Provenge BLA: advisory panel expected in March 2007; PDUFA date mid-May 2007.
DNDN – 9902b study: enrollment complete in 2007; interim data look 1H08.
FRX - Milnacipran in fibromyalgia: see CYPB.
GILD – Viread for HBV: phase-3 results 4Q07, NDA (if successful) 1H08.
GILD – GS9190 for HCV: start phase-1 any day.
GPCB – Satraplatin SPARC trial: final overall survival: fall 2007. (The trial hit the primary PFS endpoint on 9/24/06; interim OS look announced on 6/8/06 failed to meet threshold for unblinding.)
GTCB – ATryn EU launch for HD: June, 2007.
GTCB – ATryn DIC program in EU: start of ph-2 (by Leo Pharma) any day.
GTCB – ATryn ph-3 for HD in U.S.: complete enrollment 1H07, submit BLA 2H07.
GTCB – Merrimack MM-093 phase-2b in RA, phase-2 in psoriasis to be presented at EULAR in June 2007.
GTOP – Final MyVax results Dec 07.
IDIX – Tyzeka for HBV action date in EU, China: early 2007 (approved by FDA 10/25/06).
IDIX – Tyzeka phase-3 in decompensated liver disease: enrollment complete in 1Q07 (75% complete as of 9/27/06).
IDIX – NM283+ribavirin drug-interaction study: preliminary data at EASL.
IMCL – (See #msg-9218093 for selected Erbitux trials):
1) CRSYTAL trial in first-line CRC hit its PFS endpoint (announced 1/10/07); full data release at ASCO in June, 2007.
2) Erbitux in NSCLC. OS in 1st-line FLEX study: 2H07.
3) Erbitux in pancreatic cancer, SWOG trial: 1Q07.
ISA.TO - Begin European/Cdn pivotal psoriasis trials this qtr, begin U.S. pivotal psoriasis 07, complete enrollment in renal Phase IIb & also interim renal data 1st qtr 07.
ITMN – Phase-1 PK data for ITMN-191: 2H07.
JNJ: CoStar (CONR) data from U.S. pivotal trial: March 2007 at ACC
LBPFF – see DDSS
Merrimack: see GTCB
MS.TO - Complete enrollment in pivotal Secondary Progressive MS trial this year, possible interim results 2007, trial results in 2008.
Novocell – see SRDX
NRMX, NRM.TO – North American Alzhemed trial complete Jan 07, results to follow. European Alzhemed trial complete 1H08 (?). Kiacta (Fibrillex) received an approvable letter on 8/11/06.
NRPH – NRP104 in pediatric ADHD: approvable letter 10/6/06; full approval pending DEA scheduling.
NVS – Galvus PDUFA date late Feb 2007.
NVS – Tekturna PDUFA date mid Mar 2007.
NVS – Tifacogin: enrollment complete 1H07 (#msg-15157973).
PHRM – See GPCB.
PPHM - Bavituximab phase 1B HCV; four doses monotherapy over 14 days, followed for 12 weeks post-therapy, in previous non-responders/relapsers. Patient enrollment completed Oct 24, trial results due 1Q 07.
PPHM - solid tumor 8-week chemo & Bavituximab combination therapy, info due 1Q '07.
RPRX
Proellex
*Uterine Fibroids Phase 2 (U.S.) Full Phase 2 data (mid-2007)
*One year extension data (4Q2007)
*Initiate pivotal trials (YE2007)
*Endometriosis Phase 1/2 (Europe) Full Phase 1/2 data (3Q2007)
*Initiate U.S. Phase 2 (mid-2007)
Androxal
*Male Secondary Hypogonadism Non-pivotal Phase 3 (U.S.) Full non-pivotal Phase 3 data (3Q2007)
*Initiate first pivotal Phase 3 (around YE2007)
SGP – Ph-2 data for SCH 503034 in HCV: 2H07
SNY – Acomplia PDUFA date: 4/26/07.
SNY – Plavix litigation: trial begins 1/22/07.
Speedel – See NVS.
SPPI – See GPCB.
SRDX - Novocell phase-1/2 trial in type-1 diabetes: late summer 2007 (enrollment complete 8/30/06).
TH.TO -Begin confirmatory TH9507 HIV Associated Lipodystropy trial 1st qtr/07
VRTX – PROVE-1/PROVE-2/PROVE-3 timetable: see #msg-12267294
YMI – AeroLEF final results any day (interim results announced on 9/27/06 failed to meet threshold).
--
Procedure For Updating Clinical-Trials List
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old list. You can find a pointer to this list in the iBox at the top of the main message-board screen.
2. Make your additions or modifications, inserting any new items in alphabetical order.
3. Post the updated text in a new message in reply to the message with the old list.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.